Archives

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

Autio KA, Boni V, Humphrey RW, Naing A. Clin Cancer Res. 2020 26(5): 984-989. doi:10.1158/1078-0432.CCR-19-1457.

Learn More

Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Giesen D, Broer LN, Lub-de Hooge MN, et al. Clin Cancer Res. January 17, 2020; doi: 10.1158/1078-0432.CCR-19-3137.

Learn More

QSP Model of a Masked Tumor-Activated Antibody Video Abstract

Video accompanying Stroh et al. “Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody.” CPT Pharmacometrics Syst. Pharmacol. (2019). doi: 10.1002/psp4.12448

Learn More

Antibody prodrugs for cancer

Expert Opinion on Biological Therapy; Kavanaugh, W. Michael; Published Online December 2019.

Learn More

Nonclinical Development of Probody Drug Conjugates

Richardson, J. (2019, September) Nonclinical Development of Probody Drug Conjugates. Presented at the Charles River 25th Annual Biotech Symposium: Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development. Carlsbad, CA.

Learn More

Designing In and Around Tolerability Considerations for Immunotherapy Combinations

Clinical Pharmacology & Therapeutics; Stroh, M.; April 2018.

Learn More

Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody

CPT: Pharmacometrics and Systems Pharmacology; Stroh, M., et al; May 2019.

Learn More